Indoco Remedies Ltd Analyst Rating
based on 5 analysts
20.00%
Buy
40.00%
Hold
40.00%
Sell
Based on 5 analysts offering long term price targets for Indoco Remedies Ltd. An average target of ₹312.4
Source: S&P Global Market Intelligence
Indoco Remedies Ltd Share analysis
Indoco Remedies Ltd price forecast by 5 analysts
Upside of2.66%
High
₹338
Target
₹312.40
Low
₹290
Indoco Remedies Ltd target price ₹312.4, a slight upside of 2.66% compared to current price of ₹299.8. According to 5 analysts rating.
Excluding Excise Duty and Other Income, represents Net Revenue
Indoco Remedies Ltd revenue growth forecast
Expected growth rate Q1, FY2026:12.93%
Forecast
Actual
Including amortisation and stock based compensations
Indoco Remedies Ltd EPS growth forecast
EPS estimate Q1, FY2026:25.84%
Forecast
Actual
Source: S&P Global Market Intelligence
Indoco Remedies Ltd Performance
Day's Low
Day's High
₹298.5₹30552 Week's Low
52 Week's High
₹286.6₹415
| Returns % | |
| 1 Month Return | -8.91 % |
| 3 Month Return | -13.51 % |
| 1 Year Return | -13.23 % |
| Market Stats | |
| Previous Close | ₹304.30 |
| Open | ₹303.00 |
| Volume | 56.65K |
| Upper Circuit | - |
| Lower Circuit | - |
| Market Cap | ₹2,805.10Cr |
Indoco Remedies Ltd Key Statistics
| P/E Ratio | 95.39 |
| PEG Ratio | -10.48 |
| Market Cap | ₹2,805.10 Cr |
| P/B Ratio | 2.69 |
| EPS | 10.52 |
| Dividend Yield | 0.46 |
| Sector | Pharmaceuticals |
| ROE | 10.83 |
Indoco Remedies Ltd Peer Comparison
Company | Analyst View | Market Cap | 5 Year CAGR | Debt to Asset Ratio | Net Profit | Yearly Revenue |
|---|---|---|---|---|---|---|
| HOLD | ₹2,805.10 Cr | 19.46% | 0.67 | ₹97 Cr | ₹1,817 Cr | |
| HOLD | ₹32,572.86 Cr | 131.85% | 0.52 | ₹300 Cr | ₹1,051 Cr | |
| BUY | ₹18,008.87 Cr | 29.69% | 0.57 | ₹72 Cr | ₹6,702 Cr | |
| NA | ₹6,359.97 Cr | 4.48% | 0.79 | -₹388 Cr | ₹75 Cr | |
| BUY | ₹16,029.93 Cr | 50.12% | 0.68 | ₹218 Cr | ₹1,296 Cr |
Indoco Remedies Ltd Mutual Fund Holdings
About Indoco Remedies Ltd
Share Price: ₹299.80 per share as on 21 Nov, 2024 04:01 PM
Market Capitalisation: ₹2,805.10Cr as of today
Revenue: ₹430.66Cr as on September 2024 (Q3 24)
Net Profit: ₹-10.01Cr as on September 2024 (Q3 24)
Listing date: 14 Jan, 2005
Chairperson Name: Suresh G Kare
| Organisation | Indoco Remedies Ltd |
| Headquarters | Mumbai |
| Industry | Pharmaceuticals |
| E-voting on shares | Click here to vote |
Key events for Indoco Remedies Ltd
Indoco Remedies Gains After USFDA Drug Approval - 30 Oct, 2024
Indoco Remedies Limited announced USFDA approval for its Varenicline tablets, a smoking cessation drug, resulting in a significant rise in share price. The approval supports the company's growth in the US market.
Indoco Remedies Faces Challenges Amidst Target Rating - 28 Oct, 2024
Prabhudas Lilladher maintains an 'Accumulate' rating for Indoco Remedies with a target price of Rs 320, citing low margins and muted US sales. The company's Goa Unit 2's OAI status hampers growth, but a potential margin recovery is anticipated. EPS estimates for FY26/FY27 have been cut due to these challenges.
Indoco Remedies Reports Significant Financial Declines - 25 Oct, 2024
Indoco Remedies announced a 16.24% drop in net sales and a 61.41% decline in net profit for September 2024. Q2 results revealed a loss of ₹9.57 crore, with revenue down 10.19% YoY, indicating ongoing financial struggles and operational inefficiencies.
Indoco Remedies Reports Significant Q2 Losses - 24 Oct, 2024
Indoco Remedies Limited reported a net loss of Rs 95.7 million for Q2 FY25, a stark contrast to last year's profit. Revenue also declined significantly, leading to a 61% drop in PAT. Supply constraints impacted international business performance.
Indoco Remedies Faces Regulatory Setback from USFDA - 14 Oct, 2024
Indoco Remedies' Goa facility received an Official Action Indicated (OAI) classification from the USFDA following a July 2024 inspection, indicating significant compliance issues. This marks the second OAI status for the facility, impacting share prices negatively.
Indoco Remedies Retains OAI Status After Inspection - 11 Oct, 2024
Indoco Remedies announced that its Goa Plant-II & III retained the Official Action Indicated (OAI) status following a July 2024 USFDA inspection. The company is working on remedial actions expected to be completed by Q3 2024, while also receiving approval for Cetirizine Hydrochloride Tablets. Shares fell by 1.65% to ₹336.95.
Indoco Remedies Gains USFDA Approval for Allergy Drug - 04 Oct, 2024
Indoco Remedies has received final USFDA approval for its generic Cetirizine Hydrochloride Tablets, leading to a 3% surge in share price. This approval enhances Indoco's OTC portfolio and commitment to affordable healthcare solutions.
Insights on Indoco Remedies Ltd
Insights help you understand the recent movement of the company's critical parameters, giving you an overall view of the company.
POSITIVE IMPACTRevenue Rich
Revenue is up for the last 2 quarters, 432.52 Cr → 434.22 Cr (in ₹), with an average increase of 0.4% per quarter
- POSITIVE IMPACT
FII Holding Up
Foreign Institutions have increased holdings from 1.47% to 1.70% in Sep 2024 quarter
- POSITIVE IMPACT
Retail Holding Up
Retail Investor have increased holdings from 21.07% to 21.28% in Sep 2024 quarter
NO EFFECTAgainst Peers
In the last 1 year, Divis Laboratories Ltd has given 58.6% return, outperforming this stock by 71.8%
- NO EFFECT
Against Peers
In the last 3 years, Sun Pharmaceuticals Industries Ltd has given 130.6% return, outperforming this stock by 153.5%
- NO EFFECT
Promoter Holding Unchanged
Promoters holdings remained unchanged at 58.75% of holdings in Sep 2024 quarter
NEGATIVE IMPACTProfit Down
Netprofit is down for the last 3 quarters, 22.7 Cr → -9.57 Cr (in ₹), with an average decrease of 276.9% per quarter
- NEGATIVE IMPACT
MF Holding Down
Mutual Funds have decreased holdings from 17.04% to 16.74% in Sep 2024 quarter
- NEGATIVE IMPACT
Price Dip
In the last 1 year, INDOCO stock has moved down by -13.2%
Indoco Remedies Ltd Financials
Index Inclusions
Indoco Remedies Ltd Shareholding Pattern
| Investors | Holdings % | FY Quarter | 3M change |
|---|---|---|---|
| Promoter Holdings | 58.75% | 0.00 | |
| Foreign Institutions | 1.7% | 15.13 | |
| Mutual Funds | 16.74% | ||
| Retail Investors | 21.28% | 0.98 | |
| Others | 1.54% |
Indoco Remedies Ltd Key Indicators
Indoco Remedies Ltd Valuation
Indoco Remedies Ltd in the last 5 years
Lowest (-705.32x)
April 24, 2019
Industry (54.42x)
November 19, 2024
Today (95.39x)
November 19, 2024
Highest (242.71x)
September 6, 2018
Indoco Remedies Ltd Earnings and Dividends
Indoco Remedies Ltd Earnings Results
Indoco Remedies Ltd’s net profit fell -127.28% since last year same period to ₹-9.57Cr in the Q2 2024-2025. On a quarterly growth basis, Indoco Remedies Ltd has generated -465.27% fall in its net profits since last 3-months.
Read More about Earnings ResultsIndoco Remedies Ltd Dividends May,2024
In the quarter ending March 2024, Indoco Remedies Ltd has declared dividend of ₹1.50 - translating a dividend yield of 1.23%.
Read More about Dividends
Indoco Remedies Ltd Technicals Summary
Bearish
Neutral
Bullish
Indoco Remedies Ltd is currently in a Bearish trading position according to technical analysis indicators.
FAQs on Indoco Remedies Ltd
- Get a PAN card.
- Open a Demat account.
- Open a Trading account.
- Link your Demat account to your Trading account.
- Fund your Trading account.
- Place an order to buy Indoco Remedies Ltd shares.
Indoco Remedies Ltd (INDOCO) share price today is ₹299.8
Indoco Remedies Ltd is listed on NSE
Indoco Remedies Ltd is listed on BSE
- Today’s highest price of Indoco Remedies Ltd is ₹305.
- Today’s lowest price of Indoco Remedies Ltd is ₹298.5.
PE Ratio of Indoco Remedies Ltd is 95.39
PE ratio = Indoco Remedies Ltd Market price per share / Indoco Remedies Ltd Earnings per share
Today’s traded volume of Indoco Remedies Ltd(INDOCO) is 56.65K.
Today’s market capitalisation of Indoco Remedies Ltd(INDOCO) is ₹2805.1Cr.
| Indoco Remedies Ltd(INDOCO | Price |
|---|---|
52 Week High | ₹415 |
52 Week Low | ₹286.6 |
Indoco Remedies Ltd(INDOCO) share price is ₹299.8. It is down -27.76% from its 52 Week High price of ₹415
Indoco Remedies Ltd(INDOCO) share price is ₹299.8. It is up 4.61% from its 52 Week Low price of ₹286.6
| Indoco Remedies Ltd(INDOCO | Returns |
|---|---|
1 Day Returns | -4.5% |
1 Month Returns | -8.91% |
3 Month Returns | -13.51% |
1 Year Returns | -13.23% |